Research Article

Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group

Hyeong Dong Yuk, 1 Jung Kwon Kim, 2 Chang Wook Jeong, 1 Cheol Kwak, 1 Hyeon Hoe Kim, 1 and Ja Hyeon Ku 1

1 Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea
2 Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

Correspondence should be addressed to Ja Hyeon Ku; randyku@hanmail.net

Received 8 April 2018; Revised 6 August 2018; Accepted 16 August 2018; Published 6 September 2018

Objective. Although transurethral resection of bladder tumor (TURBT) is a standard treatment and determines staging for nonmuscle invasive bladder cancer, many deficiencies persist. There is a risk of upstaging and residual cancer when repeat TURBT is performed. Authors compared the results of repeat TURBT by institution performing the initial TURBT.

Methods. We retrospectively reviewed the medical records of 289 patients who underwent repeat TURBT within 2-6 weeks after initial TURBT between 1998 and 2013. The patients were divided into the referred group and the nonreferred group by institution performing the initial TURBT. And we analyzed the intergroup differences in residual tumor and upstaging rate and the factors significantly correlated with residual tumor.

Results. The mean age was 69.6 ± 11.1 years and the mean follow-up was 49.7 (range: 0–191) months. The referred group included 69 patients, while the nonreferred group included 220 patients. The referred group included 57 (82.6%) patients with residual tumor after repeat TURBT. Overall upstaging occurred in 15 (21.7%), and upstaging to T2 occurred in 11 (15.9%) of the initial Ta and T1 patients. In the nonreferred group, there were 123 (55.9%) patients with residual tumor. Overall upstaging occurred in 10 (4.5%) and upstaging to T2 occurred in 7 (3.2%) patients.

Conclusions. Gross hematuria, grade, and tumor quantity and size were significantly associated with residual cancer on multivariate analysis. In the referred group, repeat TURBT and restaging are necessary.

1. Introduction

Bladder cancer, the seventh most common cancer in the world [1], is highly prevalent in the United States, Europe, and Egypt. More than 400,000 people are diagnosed every year worldwide [2]. Approximately 75–85% of bladder cancer patients have nonmuscle invasive bladder cancer, for which transurethral resection of bladder tumor (TURBT) is the standard treatment.[3] As with any cancer, staging accuracy is important because treatment can vary depending on pathology results. Stage is determined by histology, grade, and invasion depth. Depending on stage, treatment methods such as TURBT, intravesical Bacillus Calmette–Guérin vaccine, chemotheragent instillation, and radical cystectomy are used.[4] Staging can be determined through TURBT; however, the accuracy is not always precise since tumors might not be immediately visible under the mucosa.[5] In cases of such invisible tumors, exact extent and depth cannot be precisely determined. Therefore, there is a risk of upstaging and residual cancer when repeat TURBT is performed. Many previous studies have discussed the importance of repeat TURBT for this reason. In cases of incomplete initial TURBT, no muscle in the specimen after the initial resection (with the exception of TaGl tumors and primary carcinoma in situ
for residual tumor rate, overall upstaging rate, and conversion presented as percentage of incidents. Each group was analyzed or quartile range (IQR), and categorical variables were expressed as mean values with standard deviation (SD). Secondary end point is the upstaging. The continuous variables expressed as mean values with standard deviation (SD).

2. Materials and Methods

2.1. Study Sample. The Institutional Review Board at our center approved this study (H1704-149-848). We conducted a retrospective study. It was exempt from the requirement of informed consent from the patient. All research plans and related research plans followed the Helsinki Declaration Guidelines. We analyzed the medical records of 289 patients who underwent repeat TURBT at Seoul National University Hospital (SNUH) between 1998 and 2013. The selection criteria are as follows. Cases of initial and repeat TURBT intervals 2-6 weeks. The exclusion criteria are as follows. We excluded patients with incomplete early TURBT with massive mass, patients with distant metastasis before surgery, patients with upper urinary tract cancer, and patients who underwent preoperative chemotherapy.

2.2. Study Design. The patients were divided into the referred group and the no-referred group by institution performing the initial TURBT. The nonreferred group performed both initial TURB and repeat TURB in SNUH. In the referred group, initial TURB was performed at another hospital and repeat TURB was performed at SNUH. Most of referred group patients came to SNUH for a second opinion after undergoing an initial TURBT in another hospital. Some of the referred group patients were referred for radical cystectomy at other hospitals. All patients provided their previous medical records and pathological slides obtained with the initial TURBT. Patients in the nonreferred group underwent repeat TURBT according to EAU guidelines after the initial TURBT here at SNUH. Repeat TURBT was performed with removal of the previous TURBT site including the muscularis propria layer and resection of the suspected site. In addition, cold cup biopsies were performed including six sites of anterior wall, posterior wall, both lateral walls, dome, trigone, and prostate. All patients underwent general or spinal anesthesia. Postoperative records included tumor location, size, shape, and quantity. Pathologic classification was performed by experienced two genitourinary pathologists.

2.3. Statistical Analysis. We compared tumor remaining and upstaging rates between the referred and nonreferred groups. The primary end point is the residual tumor and the secondary end point is the upstaging. The continuous variables were expressed as mean values with standard deviation (SD) or quartile range (IQR), and categorical variables were presented as percentage of incidents. Each group was analyzed for residual tumor rate, overall upstaging rate, and conversion rate to T2 according to initial TURBT stage (Ta and T1). We analyzed factors related to presence of residual tumor using univariate and multivariate logistic regression analysis. Statistical significance was considered when the p value was less than 0.05. IBM SPSS Statistics version 22.0 (IBM, Armonk, New York, USA) was used.

3. Results and Discussion

The total number of patients was 289: 69 in the referred group and 220 in the nonreferred group. The referred group consisted of patients referred from 32 regional hospitals and 26 university hospitals. 31 patients from regional hospitals and 38 patients from university hospitals visited for a voluntary second opinion and treatment. The mean age was 69.6 ± 11.1 years and the mean follow-up period was 49.7 (range: 0–191) months. The results of the initial TURBT pathology were as follows. The nonreferred group had 33 (15%) and 187 (85.0%) patients with Ta and T1, respectively, while the referred group had 15 (21.7%) and 54 (78.3%) patients with T1 and T1, respectively. Patients with CIS comprised 20 (9.0%) in the nonreferred group and 4 (5.8%) in the referred group. There were 113 (51.3%) and 35 (50.7%) patients with multifocal tumors, and 68 (30.9%) and 14 (20.3%) patients had tumors > 3 cm (Table 1). Residual tumor was reported in 123 (55.9%) of 220 patients who underwent repeat TURBT in the nonreferred group, overall upstaging was reported in 10 patients (4.5%), and upstaging to T2 occurred in 1 (3.0%) and 6 (3.2%) patients with initial Ta and T1. Of the 69 patients in the referred group, 52 (82.6%) reported residual cancer and overall upstaging was reported in 15 (21.7%). Upstaging to T2 occurred in only 11 (15.9%) patients with T1 (Tables 2 and 3).

We used both univariate and multivariate logistic regression models to analyze the factors associated with residual tumors after initial TURB. We analyzed sex, body mass index, muscularis propria layer inclusion, period of primary recurrence, number of previous TURBT procedures, previous intravesical therapy, and T stage as factors related to residual tumor. Gross hematuria, 2004 WHO/ISUP grade (low vs. high) (p = 0.006), concomitant CIS (p = 0.011), and tumor quantity (p = 0.014) were significantly associated with residual tumor after repeat TURBT on univariate analysis. The gross hematuria included in the analysis is the presence of initial symptoms before initial TURB. When univariate and multivariate analysis were performed, gross hematuria, number of previous TURBT, tumor grade, tumor multiplicity, concomitant CIS, and tumor size referred status were significant factors to affect residual tumors (Table 4). And in multivariate analysis of factors affecting upstaging, T stage, number of previous TURBT, and LVI were important factors (Table 5).

Although TURBT is a standard treatment for nonmuscle invasive bladder cancer, many deficiencies persist. Many studies have reported that clear resection does not work well, residual tumor remains, and understaging is common [6, 7, 11]. Therefore, restaging reportedly requires repeat TURBT [8, 13]. Various studies reported residual tumor after repeat TURBT in 27.3–77.6% and upstaging in 1.7–33.3% of cases [8–15].
Here we reported on 289 patients who underwent repeat TURBT after initial TURBT. Patients with previous recurrent history of TURBT were 17 (7.7%) in the nonreferred group and 60 (87.0%) in the referred group. There were many patients with recurrent repeat TURBT records in the referred group, and the ratios of T1 to T2 were 6 (3.2%) and 11 (20.4%), respectively. These results suggest that the referred group had more relapses after TURBT and more T2 patients than the nonreferred group. Because of dissatisfaction with previous treatment or the recommendation of radical cystectomy for T2, the patients often visited a larger hospital for a second opinion or other treatment. The rates of residual tumor were 57 (82.6%) in the referred group and 123 (55.9%) in the nonreferred group when repeat TURBT was performed. The rates of residual tumor after repeat TURBT were 27.3–72.3% for Ta, 32.9%–77.6% for T1, 6.5–33.3% for Ta upstaging, and 1.7–23.3% for T1 in various studies [10–12, 15]. Although the comparison is difficult due to the lack of the same conditions, these studies show that the numerical values tend to be higher in the group as in our study (Table 6) [10–12, 15]. The intergroup differences are considered to reflect the difference in surgeon proficiency and experience of the initial TURBT stage. Specimen quality can vary by surgeon experience as well as tumor size, multiplicity, and lesion. Differences in the quality of these specimens affect diagnosis [16, 17]. And the mean stage is likely to be higher than that of the nonreferred group.

The high rate of residual tumor and upstaging in the referred group compared to the nonreferred group indicates that repeat TURBT and restaging are usually needed for referred patients. Some studies recommend active surveillance for Ta stage or reconsideration of the need for repeat TURBT [18–20]. However, the upstaging rate in patients with initial Ta was 8–33% in various studies [10–12, 15]. In our study, the upstaging rate was 16.6% overall, and in some cases upstaging for T2 and repeat TURBT for Ta stage is considered necessary.

In the present study, factors associated with residual tumor after repeat TURB were gross hematuria, grade, concomitant CIS, and tumor quantity on univariate analysis and

---

**Table 1:** Characteristics of patients at the initial transurethral resection.

| Clinical characteristics | Non-referred group | Referred group | P value |
|--------------------------|--------------------|---------------|---------|
| Number of patients       | 220                | 69            | 0.998   |
| Sex                      |                    |               |         |
| Male                     | 186 (84.5%)        | 59 (85.5%)    |         |
| Female                   | 34 (15.5%)         | 10 (14.5%)    |         |
| BMI                      | 23.9±2.9           | 24.0±3.0      | 0.878   |
| Gross hematuria           | 173 (79.0%)        | 53 (76.8%)    | 0.828   |
| Number of previous TURBT | ≤2                 | 0.001         |
| 0                        | 203 (92.3%)        | 9 (13.0%)     |         |
| 1                        | 9 (4.1%)           | 52 (75.4%)    |         |
| ≥2                       | 8 (3.6%)           | 8 (11.6%)     |         |
| Previous intravesical therapy | 6 (2.7%)      | 9 (13.0%)     | 0.002   |
| T stage                   |                    | 0.260         |
| Ta                       | 33 (15.0%)         | 15 (21.7%)    |         |
| T1                       | 187 (85.0%)        | 54 (78.3%)    |         |
| Tumor grade              |                    | 0.779         |
| Low                      | 32 (14.5%)         | 21 (30.4%)    |         |
| High                     | 188 (85.5%)        | 48 (69.6%)    |         |
| Tumor multiplicity       | ≤2                 | 0.001         |
| 1                        | 107 (48.7%)        | 34 (49.3%)    |         |
| 2-7                      | 89 (40.4%)         | 30 (43.5%)    |         |
| >8                       | 24 (10.9%)         | 5 (7.2%)      |         |
| Tumor size               | ≤3cm               | 0.001         |
| 152 (69.1%)              | 55 (79.7%)         |         |
| ≥3cm                     | 68 (30.9%)         | 14 (20.3%)    |         |
| Concomitant CIS          | 20 (9.0%)          | 4 (5.8%)      | 0.006   |
| LVI                      | 9 (4.1%)           | 0 (0.0%)      | 0.190   |

BMI: body mass index; TURBT: transurethral resection of bladder tumor; CIS: carcinoma in situ; LVI: lymphovascular invasion.
Table 2: Residual tumor and upstaging results after repeat TURBT in patients.

|          | Non-referred group (N=220) | Referred group (N=69) | P value |
|----------|----------------------------|-----------------------|---------|
| Ta at initial TURBT |                           |                       |         |
| Number of patients | 33                         | 15                    |         |
| Residual tumor | 19 (57.6%)                 | 10 (66.7%)            | 0.210   |
| Overall upstaging | 4 (12.1%)                 | 4 (26.7%)             | 0.551   |
| Upstaging to T2 | 1 (3.0%)                   | 0 (0%)                | 0.496   |
| No residual tumor | 14 (42.4%)               | 5 (33.3%)             | 0.210   |
| T1 at initial TURBT |                           |                       |         |
| No. of patients | 187                       | 54                    |         |
| Residual tumor | 104 (55.6%)               | 47 (87.0%)            | <0.001  |
| Overall upstaging | 6 (3.2%)                 | 11 (20.4%)            | <0.001  |
| Upstaging to T2 | 6 (3.2%)                   | 11 (20.4%)            | <0.001  |
| No residual tumor | 83 (44.4%)               | 7 (13.0%)             | <0.001  |
| Overall |                           |                       |         |
| No. of patients | 220                       | 69                    |         |
| Residual tumor | 123 (55.9%)               | 57 (82.6%)            | <0.001  |
| Overall upstaging | 10 (4.5%)                 | 15 (21.7%)            | <0.001  |
| Upstaging to T2 | 7 (3.2%)                   | 11 (15.9%)            | <0.001  |
| No residual tumor | 97 (44.1%)               | 12 (17.3%)            | <0.001  |

TURBT: transurethral resection of bladder tumor.

Table 3: Pathologic results after repeat TURBT in patients.

|          | Non-referred group | T stage after re-TURBT (%) | Referred group |
|----------|--------------------|----------------------------|---------------|
| Initial T | N                  | T0 (Ta) | Ta (T1) | T2 | CIS |
| Ta       | 33                 | 14 (42.4%) | 11 (33.3%) | 3 (9.1%) | 1 (3.0%) | 4 (12.1%) |
| T1       | 187                | 83 (44.4%) | 40 (21.4%) | 41 (21.9%) | 6 (3.2%) | 17 (9.1%) |
| Referred group | N | T0 (Ta) | T0 (T1) | T2 | CIS |
| Ta       | 15                 | 5 (33.3%) | 4 (26.7%) | 4 (26.7%) | 0 (0%) | 2 (13.3%) |
| T1       | 54                 | 7 (13.0%) | 4 (7.4%) | 24 (44.4%) | 11 (20.4%) | 8 (14.8%) |

TURBT: transurethral resection of bladder tumor.

gross hematuria, grade, tumor quantity, and tumor size on multivariate analysis. Cano-Garcia and Donat also indicated a significant relationship between residual tumor and size [21, 22]. Kamiya et al. suggested that tumor multiplicity may be a related factor in residual tumors [23]. Considering repeat TURBT, these factors may be helpful. Several tumor markers have recently been approved by the FDA for early diagnosis of bladder cancer [24]. These tumor markers will have higher sensitivity than urine cytology and will replace the cystoscopy test. Cystoscopy is less effective and invasive than urinary biomarker test. The development of this biomarker will be associated with high grade NMIBC diagnosis and contribute to the differentiation of residual tumor and accuracy of staging [25–27].

There are several limitations of this study. First, this is a single center observational study. Second, there may be selection bias due to the retrospective nature. Third, there may be sampling bias due to variability among the institutions and relatively long data collection period.

4. Conclusions

This study is the first comparison between the referred and the nonreferred groups with repeat TURBT. The referred group has a relatively higher initial TURBT stage, residual tumor, overall upstaging, and upstaging to T2 than the non-referred group. It is thought that this is due to the difference of the operator’s experience and the initial stage of the two groups. In the referred group, repeat TURBT and restaging are necessary, while repeat TURBT for Ta stage cancer is also necessary. The factors associated with residual tumor after initial TURBT were gross hematuria, grade, concomitant CIS, tumor quantity, and tumor size. These factors may be helpful in determining repeat TURBT.

Data Availability

Data used to support the findings of this study are restricted by the Seoul National University Hospital Clinical Research
Table 4: Factors of residual tumor at the repeat TURBT according to univariate and multivariate logistic regression models.

|                          | Univariate |         |         | Multivariate |         |
|--------------------------|------------|---------|---------|--------------|---------|
|                          | OR         | 95% CI  | p-value | OR           | 95% CI  | P value |
| Sex                      | 1.36       | 0.70-2.76 | 0.381   | 1.05         | 0.47-2.39 | 0.913   |
| BMI                      | 0.95       | 0.88-1.03 | 0.233   | 0.98         | 0.89-1.07 | 0.625   |
| Number of previous TURBT |            |         |         |              |         |         |
| 0                        | Reference  | Reference |         |              |         |         |
| 1                        | 10.38      | 4.00-26.95 | <0.001 | 6.49         | 1.35-31.06 | 0.019   |
| 2                        | 6.49       | 1.44-29.26 | 0.015   | 11.56        | 1.45-92.10 | 0.021   |
| Previous intravesical therapy | 1.22 | 0.42-4.02 | 0.719   | 0.10         | 0.01-0.65 | 0.017   |
| Gross hematuria           | 1.90       | 1.07-3.36 | 0.027   | 2.457        | 1.245-4.850 | 0.010   |
| T stage (Ta/T1)           | 0.91       | 0.49-1.74 | 0.770   | 1.06         | 0.45-2.51 | 0.901   |
| Tumor grade at initial TURBT (Low/High) | 3.05  | 1.56-6.13 | <0.001 | 2.56         | 1.13-6.04 | 0.026   |
| Concomitant CIS (yes/no)  | 8.23       | 2.86-34.80 | <0.001 | 8.06         | 2.43-37.62 | 0.002   |
| LVI                      | 2.16       | 0.51-14.71 | 0.341   | 2.51         | 0.50-18.91 | 0.298   |
| Tumor multiplicity at initial TURBT |        |         |         |              |         | 0.029   |
| 1                        | Reference  | Reference |         |              |         |         |
| 2-7                      | 1.86       | 1.07-3.24 | 0.027   | 2.06         | 1.11-3.81 | 0.021   |
| ≥8                       | 3.21       | 1.26-8.14 | 0.014   | 2.85         | 1.05-7.73 | 0.040   |
| Tumor size at initial TURBT (<3 cm/≥3 cm) | 1.88 | 1.13-3.18 | 0.016   | 1.925        | 1.014-3.656 | 0.045   |
| Referred/Non-referred status | 3.75 | 1.96-7.68 | <0.001 | 3.47         | 1.03-11.20 | 0.036   |

BMI: body mass index; TURBT: transurethral resection of bladder tumor; CIS: carcinoma in situ; LVI: lymphovascular invasion.

Table 5: Factors of upstaging at the repeat TURBT according to univariate and multivariate logistic regression models.

|                          | Univariate |         |         | Multivariate |         |
|--------------------------|------------|---------|---------|--------------|---------|
|                          | OR         | 95% CI  | p value | OR           | 95% CI  | p value |
| Sex                      | 0.35       | 0.08-1.03 | 0.094   | 0.27         | 0.06-0.85 | 0.045   |
| BMI                      | 1.00       | 0.0-1.12 | 0.961   | 1.02         | 0.90-1.15 | 0.793   |
| Number of previous TURBT |            |         |         |              |         |         |
| 0                        | Reference  | Reference |         |              |         |         |
| 1                        | 1.75       | 0.82-3.72 | 0.144   | 1.15         | 0.29-4.64 | 0.838   |
| 2                        | 5.56       | 1.91-16.21 | 0.002   | 5.36         | 1.21-23.78 | 0.027   |
| Previous intravesical therapy | 2.03 | 1.37-3.05 | <0.001 | 0.76         | 0.15-3.18 | 0.718   |
| Gross hematuria           | 2.45       | 1.00-7.36 | 0.071   | 3.18         | 1.20-10.27 | 0.031   |
| T stage (Ta/T1)           | 2.10       | 0.96-4.37 | 0.050   | 3.32         | 1.30-3.47 | 0.011   |
| Tumor grade at initial TURBT (Low/High) | 2.58 | 0.88-11.03 | 0.127   | 3.74         | 1.06-18.40 | 0.063   |
| Concomitant CIS (yes/no)  | 1.93       | 0.80-4.30 | 0.120   | 1.24         | 0.46-3.11 | 0.656   |
| LVI                      | 1.52       | 0.97-2.37 | 0.065   | 1.38         | 0.82-2.32 | 0.218   |
| Tumor multiplicity at initial TURBT |        |         |         |              |         | 0.231   |
| 1                        | Reference  | Reference |         |              |         |         |
| 2-7                      | 1.60       | 0.80-3.19 | 0.186   | 1.63         | 0.76-3.47 | 0.209   |
| ≥8                       | 2.13       | 0.80-5.68 | 0.132   | 1.77         | 0.57-5.53 | 0.326   |
| Tumor size at initial TURBT (<3 cm/≥3 cm) | 1.14 | 0.59-2.16 | 0.696   | 1.48         | 0.66-3.26 | 0.339   |
| Referred/Non-referred status | 1.76 | 0.87-3.47 | 0.108   | 0.86         | 0.35-2.03 | 0.732   |

BMI: body mass index; TURBT: transurethral resection of bladder tumor; CIS: carcinoma in situ; LVI: lymphovascular invasion.

Institute in order to protect Patient Personal Information. Data are available from Seoul National University Hospital Clinical Research Institute for researchers who meet the criteria for access to confidential data.

**Ethical Approval**

This study design was approved by the appropriate ethics review boards.
Disclosure

The abstract was presented at the 37th Congress of the Société Internationale d’Urologie, Centro de Congressos de Lisboa, October 19-22, 2017. No funders had any role in study concept and design, experiments, analysis of data, writing manuscript, or the decision for publication.

Conflicts of Interest

There are no conflicts of interest to declare.

Authors’ Contributions

All the authors have approved the manuscript and agree with submission to the journal.

Acknowledgments

This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (Grant no. 2016R1A2B4011623).

References

[1] M. E. Goossens, F. Isa, M. Brinkman et al., “International pooled study on diet and bladder cancer: the bladder cancer, epidemiology and nutritional determinants (BLEND) study: design and baseline characteristics,” Archives of Public Health, vol. 74, no. 1, 30 pages, 2016.

[2] N. Malats, “Genetic epidemiology of bladder cancer: Scaling up in the identification of low-penetration genetic markers of bladder cancer risk and progression,” Scandinavian Journal of Urology, vol. 42, no. 218, pp. 131–140, 2008.

[3] M. Ploeg, K. K. H. Aben, and L. A. Kiemeneiy, “The present and future burden of urinary bladder cancer in the world,” World Journal of Urology, vol. 27, no. 3, pp. 289–293, 2009.

[4] M. Babijuk, A. Bohle, M. Burger et al., “EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016,” European Urology, vol. 71, no. 3, pp. 447–461, 2017.

[5] J. C. Angulo, J. I. Lopez, N. Flores, and J. D. Toledo, “The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification,” Journal of Cancer Research and Clinical Oncology, vol. 119, no. 10, pp. 578–593, 1993.

[6] M.-O. Grimm, C. Steinhoff, X. Simon, P. Spiegelhalder, R. Ackermann, and T. A. Vögti, “Effect of routine repeat transurethral resection for superficial bladder cancer: A long-term observational study,” The Journal of Urology, vol. 170, no. 21, pp. 433–437, 2003.

[7] R. Klan, V. Loy, and H. Huland, “Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder,” The Journal of Urology, vol. 146, no.2, pp. 316–318, 1991.

[8] R. T. Divrik, A. F. Ahin, U. Yildirim, M. Altok, and F. Zorlu, “Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: A prospective randomised clinical trial,” European Urology, vol. 58, no. 2, pp. 185–190, 2010.

[9] A. Brauers, R. Buettner, and G. Jakse, “Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early?” The Journal of Urology, vol. 165, no. 3, pp. 808–810, 2001.

[10] L. Schips, H. Augustin, R. E. Zigeuner et al., “Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?” Urology, vol. 59, no. 2, pp. 220–223, 2002.

[11] H. W. Herr, “The value of a second transurethral resection in evaluating patients with bladder tumors,” The Journal of Urology, vol. 162, no. 1, pp. 74–76, 1999.

[12] K. S. Han, J. Y. Joung, K. S. Cho et al., “Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: The referral cancer center experience and review of the literature,” Journal of Endourology, vol. 22, no. 12, pp. 2699–2704, 2008.

[13] A. Vianello, E. Costantini, M. Del Zingaro, V. Bini, H. W. Herr, and M. Porena, “Repeated white light transurethral resection of the bladder in nonmuscle invasive urothelial bladder cancers: Systematic review and meta-analysis,” Journal of Endourology, vol. 25, no. 11, pp. 1703–1712, 2011.

[14] S. C. Dutta, J. A. Smith Jr., S. B. Shappell, C. S. Coffey, S. S. Chang, and M. S. Cookson, “Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy,” The Journal of Urology, vol. 166, no. 2, pp. 490–493, 2001.

[15] M. A. Zurkirchen, T. Sulser, A. Gaspert, and D. Hauri, “Second transurethral resection of superficial transitional cell carcinoma of the bladder: A must even for experienced urologists,” Urologia Internationalis, vol. 72, no. 2, pp. 99–102, 2004.

[16] J. Huang, J. Fu, H. Zhan et al., “Analysis of the absence of the detrusor muscle in initial transurethral resected specimens and
the presence of residual tumor tissue,” *Urologia Internationalis*, vol. 89, no. 3, pp. 319–325, 2012.

[17] M. Roupret, D. R. Yates, J. Varinot, V. Phe, E. Chartier-Kastler, M. O. Btker et al., “The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience,” *The Canadian Journal of Urology*, vol. 19, no. 5, pp. 6459–6464, 2012.

[18] W. Oosterlinck, “Repeat transurethral resection lowers recurrence rates in T1 bladder tumors, even after intravesical mitomycin C,” *Nature Clinical Practice Urology*, vol. 3, no. 11, pp. 582–583, 2006.

[19] W. Oosterlinck, “Watchful waiting for low-grade Ta bladder tumours: The idea would have been unacceptable 30 years ago, but nowadays we are highly interested in the results of this study exploring it,” *European Urology*, vol. 49, no. 2, pp. 215–216, 2006.

[20] A. Van der Meijden, Oosterlinck W, M. Brausi, K.-H. Kurth, R. Sylvester, and C. de Balincourt, “Significance of bladder biopsies in Ta,T1 bladder tumors: A report from the EORTC genitourinary tract cancer cooperative group,” *European Urology*, vol. 35, no. 4, pp. 267–271, 1999, EORTC-GU Group Superficial Bladder Committee.

[21] M. C. Cano-Garcia, T. Fernandez-Aparicio, A. G. Hidalgo, L. Reina-Alcaina, C. Carrillo-George, and A. Rivero-Guerra, “Outpatient holmium laser treatment for recurrent low-grade superficial bladder cancer under local anesthesia,” *Minerva Urologica e Nefrologica*, vol. 68, no. 2, pp. 204–208, 2016.

[22] S. M. Donat, A. North, G. Dalbagni, and H. W. Herr, “Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm,” *The Journal of Urology*, vol. 171, no. 2 I, pp. 636–639, 2004.

[23] N. Kamiya, H. Suzuki, T. Suyama et al., “Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study,” *International Journal of Clinical Oncology*, vol. 22, no. 2, pp. 353–358, 2016.

[24] D. Terracciano, M. Ferro, S. Terreri et al., “Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers,” *Translational Research*, vol. 184, pp. 108–117, 2017.

[25] M. Olivieri, M. Ferro, S. Terreri et al., “Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis,” *Oncotarget*, vol. 7, no. 15, pp. 20636–20654, 2016.

[26] P. Gontero, R. Sylvester, F. Pisano et al., “The impact of retransurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin,” *BJU International*, vol. 118, no. 1, pp. 44–52, 2016.

[27] G. M. Busetto, M. Ferro, F. Del Giudice et al., “The prognostic role of circulating tumor cells (CTC) in High-Risk non-muscle-invasive bladder cancer,” *Clinical Genitourinary Cancer*, vol. 15, no. 4, pp. e661–e666, 2017.